PT-141 (Bremelanotide)

PT-141, also known by the brand name Bremelanotide, is a synthetic peptide used to treat sexual dysfunction by acting on the brain’s melanocortin receptors. It is an FDA-approved prescription medication for premenopausal women with hypoactive sexual desire disorder (HSDD), a condition characterized by persistently low libido that causes distress.
Key Information
Mechanism of Action: Unlike traditional ED medications (like Viagra or Cialis) that work on the vascular system, PT-141 works on the central nervous system to increase sexual desire and arousal. It stimulates specific receptors in the brain (primarily MC4R) to release neurochemicals like dopamine that are involved in sexual response.
Uses:
Women: It is FDA-approved for treating HSDD in premenopausal women.
Men: It is used off-label to treat erectile dysfunction (ED), particularly in cases where the cause is psychological or an emotional block, or when other ED medications are not effective or contraindicated (e.g., for men with certain heart problems).
Administration: PT-141 is typically administered via a subcutaneous injection (under the skin) using a small needle. Some formulations are available as a nasal spray.
Dosage and Onset: The medication is usually taken at least 45 minutes before sexual activity, and its effects can last for up to 72 hours, offering spontaneity. Dosing should not exceed eight times per month.
Side Effects: Common side effects include nausea, flushing, and headaches. It can also cause a temporary increase in blood pressure and hyperpigmentation (skin darkening). It is contraindicated in patients with known cardiovascular disease or uncontrolled hypertension.
Legal Status: It is a prescription-only medication and should only be used under the supervision of a licensed medical professional.
PT-141 provides a unique treatment option for individuals with sexual dysfunction, particularly those whose conditions stem from the central nervous system rather than circulatory issues.